We welcome your views on our website and invite you to take part in a brief survey when you've finished your visit.
Your response will help us improve the site and the experience we offer to visitors.
Some of the principal treatments carried out by Dr Sethupathi Muthuramalingam at Spire include:
I graduated from India and obtained an MD in General Medicine from one of the prestigious central institutes (JIPMER) in India. I was awarded a Gold medal by the University for the most outstanding performance in the MD examination.
My general oncology training started in the Republic of Ireland and then I spent fours years in the Oxford Medical Oncology training programme, leading to the completion of specialist training in oncology. I took part in various research activities during my training and I was awarded the American Society of Oncology Merit Award for the quality research paper abstract submitted in one of their meetings.
In 2005 I was appointed as a Consultant Medical Oncologist at Portsmouth Hospitals NHS Trust. As an oncologist with a special interest in colorectal, lung cancer and mesothelioma, my expertise is treating cancer patients with chemotherapy, biological therapies, targeted therapies and also immunotherapies. I also use molecular tests like next generation sequencing (NGS) and genetic tests to guide treatment decisions and reduce the toxicities from treatment. In addition, I take part in many clinical trials and I was the principal investigator of a few of the trials. I have extensive knowledge in managing symptoms associated with cancer and I work very closely with the palliative care and pain team.
Special clinical interests: Chemotherapy for colorectal, lung cancer and mesothelioma. Use of the biological therapies in the treatment of cancer like bevacizumab, cetuximab, Panitumumab. Use of the targeted therapies in the treatment of cancer like gefitinib, afatinib,criziotinib. Use of the immunotherapies in the treatment of cancer like Pembrolizumab, nivoulumab. Application of Molecular tests including next generation sequencing (NGS) which help to guide targeted treatments. Application of Genetic tests like DPD and MSI, which might influence treatment decision making in colorectal cancer patients.
Royal College of Physicians
Association of Cancer Physicians
American Society of Clinical Oncology
British Medical Association
European Society of Medical Oncology
Medical Defence Union
International Association of Lung Cancer
Health Volunteers Overseas
Lead for the chemotherapy services: 2009-2016 Portsmouth Hospitals NHS trust
Lead for the chemotherapy Governance and peer reviews: 2009-2016
Represented Portsmouth in the network chemotherapy network meetings: 2009-2016
Represented chemotherapy services in the Formulary Medicines Group meetings: 2011-2016 Portsmouth Hospitals NHS trust
Chair of the oncology Consultant group meetings: 2013-2014
Portsmouth Representative: 2011-2013 Regional ‘Cancer Drugs and Therapeutics Evaluation committee’ (CDTEC) meeting
Consultant Medical Oncologist, Portsmouth Haematology Oncology Centre, Queen Alexandra Hospital, Portsmouth.Back to top
I enjoy music and travelling in my free time.Back to top
|Private secretary||Deborah Otter|
|Private secretary telephone||02393 277 022 / 7880 303 665|
|Private secretary email||Deborah.Otter@genesiscare.co.uk|
11 February 2020
Redbridge-based Spire London East Hospital has been upgraded to a ‘Good’ rating following an inspection by the Care Qual…
04 February 2020
The Paterson Independent Inquiry published its final report on 4 February 2020.